Home > Riviste > Minerva Gastroenterology > Fascicoli precedenti > Articles online first > Minerva Gastroenterology 2022 May 05

ULTIMO FASCICOLO
 

JOURNAL TOOLS

Opzioni di pubblicazione
eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

Original Article   

Minerva Gastroenterology 2022 May 05

DOI: 10.23736/S2724-5985.21.03066-7

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Treatment with phosphatidylcholine of patients with non-alcoholic fatty liver disease: a prospective pilot study

Ludovico ABENAVOLI 1 , Roman MYAZIN 2, Sharmila FAGOONEE 3, Pietro CINAGLIA 1, Francesco LUZZA 1, Rinaldo PELLICANO 4, Dmitry EMELYANOV 2

1 Department of Health Sciences, University Magna Graecia, Catanzaro, Italy; 2 Department of internal diseases of the Federal State Budgetary Educational Institution of Higher Education Volgograd State Medical University of the Ministry of Health of the Russian Federation, Volgograd, Russia; 3 Institute for Biostructure and Bioimaging, National Research Council, Molecular Biotechnology Centre, Turin, Italy; 4 Unit of Gastroenterology, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy


PDF


BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is characterized by a complex clinical picture that includes non-alcoholic steatohepatitis and cirrhosis. In the last decades, several studies have shown that NAFLD increases the risk of cardiovascular diseases. In a prospective pilot study, the benefit of treatment with phosphatidylcoline in NAFLD patients has been assessed.
METHODS: Thirty patients with NAFLD were enrolled. All received treatment with phosphatidylcoline (Essentiale® Forte N) 300 mg capsules, administered 2 at time orally, 3 times a day with meals for three months. The clinical and laboratory parameters before and after treatment were compared.
RESULTS: After the administration of Essentiale® Forte N the level of alanine aminotransferase (ALT) decreased by 59.6% (p<0.05) and that of aspartate transaminase (AST) decreased by 75.4% (p<0.05). Moreover, after treatment, an increase in antioxidant enzymes superoxide dismutase by 48% (p<0.05) and glutathione peroxidase by 48.1% (p<0.05) was observed.
CONCLUSIONS: The results of the study indicate that treatment with Essentiale® Forte N for 3 months was associated with a significant decrease in transaminase levels, in the activity of lipid peroxidation markers and an increase in the level of antioxidant enzymes.


KEY WORDS: Antioxidant; Cardiovascular diseases; Diagnosis; Treatment

inizio pagina